Purchase this article with an account.
Jingyun Wang, Kai Januschowski, Charlotte Schramm, Daniel E Neely; Pilot Data on Monitoring Objective Compliance with Intermittent Occlusion Glasses Therapy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2358.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Liquid crystal glasses utilize an intermittent occlusion technique (at 30-second opaque/transparent intervals) and avoid adhesive, potentially improving compliance. Several previous studies support the effectiveness of this new occlusion therapy device for amblyopia treatment. However, previous studies had no objective compliance measured for these glasses, which limits understanding of the dose-repsonse for this treatment. This study reports the feasibility and pilot data of a microsensor to monitor objective compliance with intermittent occlusion glasses.
Six children (3-8 yr) with unilateral amblyopia associated with strabismus and anisometropia were enrolled. Prior to enrollment, they wore glasses for 12 weeks. Amblyopia was defined as an interocular visual acuity difference of at least 0.2 logMAR. At enrollment, depends on severity of amblyopia, they were prescribed 4 or 12 hours of intermittent occlusion therapy glasses (Amblyz™). An inexpensive, commercially availabe waterproof microsensor was attached to the temple arm to monitor complaince with glasses wear for 3 to 4 weeks. Compliance was defined as the percentage of hours of actual glasses wearing compared to the hours of prescribed. Daily compliance was calculated, and general compliance was the average of daily complaince. General compliance at treating days was reported.
Compliance varies among individuals. For instance, Patient A had good general compliance (average 81%), but daily compliance declined to from 110% to 60% over three weeks; Patient B had approximately 52% general compliance, with poor daily compliance on weekends compared with weekdays. General compliance was averaged at 46.4% (ranged from 16% to 81%). Daily compliance declined with time for every patient, and mean daily compliance was fitted by y=66-2*x (day), which indicated a decreasing rate of 2% per day. Neither of the patients’parents reported that the child had discomfort or social concerns related to the attached sensor.
Objective compliance with intermittent occlusion glasses can be monitored with a microsensor. Objective compliance with intermittent occlusion therapy glasses varies among individuals, but on average declines over time course. These preliminary results are limited with short-term follow-up.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only